Longacting cabotegravir and rilpivirine dosed every 2 months in adults with HIV1 infection ATLAS2M 48week results a randomised multicentre openlabel phase 3b noninferiority study

Simple item page
dc.citation.doi10.1016/S2352-3018(21)00185-5
dc.citation.epage689
dc.citation.spage679
dc.contributor.authorHans Jaeger
dc.contributor.authorEdgar T Overton
dc.contributor.authorGary Richmond
dc.contributor.authorGiuliano Rizzardini
dc.contributor.authorJaime Federico Andrade-Villanueva
dc.contributor.authorE et al
dc.date.accessioned2023-05-04T08:32:54Z
dc.date.available2023-05-04T08:32:54Z
dc.identifier.citationWOS
dc.identifier.issn2352-3018
dc.identifier.urihttps://hdl.handle.net/10539/35313
dc.journal.titleLANCET HIV
dc.journal.volume8
dc.titleLongacting cabotegravir and rilpivirine dosed every 2 months in adults with HIV1 infection ATLAS2M 48week results a randomised multicentre openlabel phase 3b noninferiority study

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Journal.pdf
Size:
459.14 KB
Format:
Adobe Portable Document Format
Description:
Journal
Download

Collections

Research Outputs (Clinical Medicine)